ARID1A loss
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ARID1A
Variant loss
Impact List unknown
Protein Effect loss of function
Gene Variant Descriptions ARID1A loss indicates loss of the ARID1A gene, mRNA, and protein.
Associated Drug Resistance
Category Variants Paths

ARID1A mutant ARID1A inact mut ARID1A loss

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A loss Her2-receptor positive breast cancer resistant Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896). 27172896
ARID1A loss Her2-receptor positive breast cancer resistant AZD8055 Preclinical - Cell culture Actionable In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896). 27172896
ARID1A loss breast cancer sensitive AZD8055 + MK2206 Preclinical - Cell culture Actionable In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896). 27172896
ARID1A loss ovarian cancer predicted - sensitive unspecified PD-L1 antibody Preclinical Actionable In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026). 29736026
ARID1A loss colon cancer predicted - sensitive unspecified PD-L1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026). 29736026
ARID1A loss ovarian clear cell carcinoma predicted - sensitive JQ1 Preclinical - Cell culture Actionable In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405). 29760405
ARID1A loss colorectal cancer sensitive Berzosertib Preclinical - Cell culture Actionable In a preclinical study, Berzosertib (VX-970) inhibited viability of a colorectal cancer cell line harboring ARID1A loss in culture (PMID: 29038346). 29038346